Lipocine (LPCN) Capital Expenditures (2012 - 2024)
Lipocine's (LPCN) quarterly Capital Expenditures came in at $10019.0 in Q4 2024, up 9.29% YoY from $9167.0 in Q1 2024, and up 9.29% on a QoQ basis from $9167.0 in Q4 2023.
Lipocine (LPCN) Capital Expenditures (2012 - 2024) Analysis & Trends
Lipocine (LPCN) has 8 years of Capital Expenditures data on file, last reported at $10019.0 in Q4 2024.
- Quarterly Capital Expenditures rose 9.29% year-over-year to $10019.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $19186.0 (up 45.71% YoY) and the FY2024 annual result came in at $90086.0, up 584.18% from the prior year.
- Capital Expenditures grew to $10019.0 in Q4 2024, from $9167.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $96732.0 in Q4 2022 to a low of $4000.0 in Q1 2023.
- A 3-year average of $26169.5 and a median of $10160.5 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 90.52% — and 2024, when it increased 9.29%.
- Tracing LPCN's Capital Expenditures over 3 years: stood at $96732.0 in 2022, then plunged by 90.52% to $9167.0 in 2023, then grew by 9.29% to $10019.0 in 2024.
- The last three Capital Expenditures figures came in at $10019.0 (Q4 2024), $9167.0 (Q4 2023), and $4000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 10,019.00 |
| Dec 31, 2024 | 10,019.00 |
| Dec 31, 2023 | 9,167.00 |
| Dec 31, 2023 | 9,167.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 96,732.00 |
| Dec 31, 2022 | 96,732.00 |
| Jun 30, 2022 | 10,302.00 |
| Jun 30, 2022 | 10,302.00 |
| Mar 31, 2022 | 26,797.00 |
| Mar 31, 2022 | 26,797.00 |
| Jun 30, 2016 | 20,448.00 |
| Jun 30, 2016 | 20,448.00 |
| Mar 31, 2016 | 39,202.00 |
| Mar 31, 2016 | 39,202.00 |
| Dec 31, 2015 | -1.00 |
| Dec 31, 2015 | -1.00 |
| Sep 30, 2015 | 13,911.00 |
| Sep 30, 2015 | 13,911.00 |